Search alternatives:
latest decrease » largest decrease (Expand Search), greatest decrease (Expand Search), largest decreases (Expand Search)
marked decrease » marked increase (Expand Search)
ad decrease » a decrease (Expand Search), awd decreased (Expand Search), _ decrease (Expand Search)
three ad » three age (Expand Search), three arm (Expand Search), three _ (Expand Search)
latest decrease » largest decrease (Expand Search), greatest decrease (Expand Search), largest decreases (Expand Search)
marked decrease » marked increase (Expand Search)
ad decrease » a decrease (Expand Search), awd decreased (Expand Search), _ decrease (Expand Search)
three ad » three age (Expand Search), three arm (Expand Search), three _ (Expand Search)
-
1
-
2
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Background<p>Umbilical cord blood (UCB)-derived CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). …”
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Background<p>Umbilical cord blood (UCB)-derived CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). …”
-
13
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Background<p>Umbilical cord blood (UCB)-derived CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). …”
-
14
Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration.
Published 2024“…<b>a</b> VEGF-A121 exhibited a change of –173.2, 95% CI [–322.8, –96.3], <i>p</i> = 0.00049, where the addition of 2 μg/mL bevacizumab markedly reduced the VEGF-A121 concentration to a median of 26.9 pg/mL, with a range of 67.3 pg/mL that partly fell below the high-accuracy threshold of 38 pg/mL. …”
-
15
-
16
-
17
-
18
-
19
-
20